Driving momentum and supporting success in neuroscience drug discovery.
Neuroscience drug discovery is complex and time-consuming. The vast majority of drug candidates fail before reaching clinical trials and for most neurodegenerative diseases, there are no disease-modifying therapies.
One of the reasons for slow progress in neuroscience drug discovery is the lack of suitable models, particularly cell models. Primary animal cells, such as isolated neurons or microglia, are often used in monoculture for phenotypic screening and lead optimization assays but these models fail to recapitulate the complexity of the brain or communication between different cell types within it.
In this webinar, our neuroscience experts will discuss the advantages of using human-induced pluripotent stem cell (iPSC)-derived cells, such as neurons, microglia, and oligodendrocytes, in drug discovery assays. We will outline how these cells can be used in complex cell cultures, combining cell types found in the brain to provide better models for neuroscience drug discovery.
In this webinar, you will:
- Hear why we need better models of brain processes for neuroscience drug discovery
- Learn more about how human iPSCs can be a source of cells for screening assays and in vitro pharmacology
- Understand how our experts have built models for myelination, neuroinflammation, and neurodegeneration, and how these models can be used in drug discovery
About the Presenters
Ludovico Buti
Senior Research Leader
Malika Bsibsi
Research Leader
Offered Free by: CG Life
See All Resources from: CG Life